🇺🇸 Rifamycin SV MMX in United States

FDA authorised Rifamycin SV MMX on 16 November 2018

Marketing authorisation

FDA — authorised 16 November 2018

  • Application: NDA210910
  • Marketing authorisation holder: COSMO TECHNOLOGIES
  • Local brand name: AEMCOLO
  • Indication: TABLET, DELAYED RELEASE — ORAL
  • Status: approved

Read official source →

Other Gastroenterology / Infectious Disease approved in United States

Frequently asked questions

Is Rifamycin SV MMX approved in United States?

Yes. FDA authorised it on 16 November 2018.

Who is the marketing authorisation holder for Rifamycin SV MMX in United States?

COSMO TECHNOLOGIES holds the US marketing authorisation.